August 23, 2017 10:51 AM ET

Pharmaceuticals

Company Overview of Takata Seiyaku Co., Ltd.

Company Overview

Takata Seiyaku Co., Ltd. manufactures and sells pharmaceuticals, soft drinks, and health food. It offers tablets and capsule formulations, freeze-dried and other injection preparations, and granulated powders and dry syrup. The company was formerly known as Masujiro Takada and changed its name to Takata Seiyaku Co., Ltd. in November 1928. Takata Seiyaku Co., Ltd. was founded in 1895 and is based in Saitama, Japan with a branch office in Tokyo, Japan. It has sales offices in Tokyo, Sapporo, Nagoya, Osaka, and Fukuoka, Japan.

1-11-1

Numakage

Minami-ku

Saitama,  336-8666

Japan

Founded in 1895

Phone:

81 4 8816 4193

Fax:

81 4 8816 4192

Key Executives for Takata Seiyaku Co., Ltd.

President & Representative Director
Compensation as of Fiscal Year 2017.

Takata Seiyaku Co., Ltd. Key Developments

Chugai Pharmaceutical Co., Ltd. Announces Favorable on 'OXAROLOintment 25 gg'

Chugai Pharmaceutical Co., Ltd. announced that a judgment had been rendered on the suit for damages with regard to Chugai's process patent (Japanese Patent No. 3310301; hereinafter referred to as "Patent") on "OXAROL® Ointment 25 g/g" (hereinafter referred to as "OXAROL Ointment"), a drug for the treatment of keratosis including psoriasis vulgaris. As announced in "The Supreme Court Rendered Favorable Judgment on Patent-Infringement Lawsuit Regarding OXAROL Ointment", Chugai has already received a favorable judgment in a lawsuit in which Chugai sought injunction against generic drug manufacturers based on infringement of the Patent. As of August 10, 2015, Chugai filed a lawsuit with the Tokyo District Court against Iwaki Seiyaku Co., Ltd., Takata Pharmaceutical Co., Ltd., and Pola Pharma Inc. (hereinafter collectively referred to as '3 companies'), manufacturers of generics of OXAROL Ointment, seeking compensation for damages for infringement of the Patent. The Tokyo District Court rendered a judgment today. The details of the judgment. The three generic drug manufacturers were determined to be liable for damages, and the following payments were ordered. 1) Defendant Iwaki Seiyaku Co., Ltd.: Payment of ¥203,632,798 and payment of 5% a year in interest from September 15, 2015 until completion of payment to the plaintiff, Chugai Pharmaceutical Co., Ltd. (hereinafter referred to as Plaintiff). 2) Defendant Takata Pharmaceutical Co., Ltd.: Payment of ¥118,159,458 and payment of 5% a year in interest from September 15, 2015 until completion of payment to the Plaintiff. 3) Defendant Pola Pharma Inc.: Payment of ¥168,223,686 and payment of 5% a year in interest from September 15, 2015 until completion of payment to the Plaintiff. 4) Defendant Iwaki Seiyaku Co., Ltd., defendant Takata Pharmaceutical Co., Ltd., defendant Pola Pharma Inc.: Jointly, payment of ¥579,169,686 and payment of 5% a year in interest from September 15, 2015 (of which ¥179,169,686, from September 1, 2016) until completion of payment to the Plaintiff.

Chugai Pharmaceutical Co., Ltd. Announces Final Victory in Lawsuit against Iwaki & Co., Ltd., Takata Seiyaku Co., Ltd., Pola Pharma Inc., and Dksh Japan K.K

Chugai Pharmaceutical Co., Ltd. announced its final victory in a lawsuit in which Chugai sought injunction against generic drug manufacturers based on infringement of the process patent on "OXAROL® Ointment 25 g/g", a Chugai's drug for treatment of keratosis including psoriasis vulgaris. On March 24, the Supreme Court rendered a judgment dismissing the appeal by the generic companies, thereby Chugai's victory in this lawsuit has become final. As of February 19, 2013, Chugai filed a lawsuit with Tokyo District Court against Iwaki & Co., Ltd., Takata Seiyaku Co., Ltd., and Pola Pharma Inc., distributors of generics of OXAROL Ointment, and also against DKSH Japan K.K., importer of the active ingredient of these generic products seeking injunction based on infringement of the Patent. As of December 24, 2014, Tokyo District Court rendered a decision that was fully in favor of Chugai's claim, and as of February 25, 2015, issued a preliminary injunction to the 4 companies. The 4 companies appealed the decision of Tokyo District Court to the Intellectual Property High Court as of January 6, 2015. The Intellectual Property High Court heard this case by the Grand Panel and as of March 25, 2016 the Grand Panel affirmed the District Court decision and dismissed the appeal by the generic companies. As of April 7, 2016, the 4 companies filed a petition with the Supreme Court to take an appeal from the judgment of Intellectual Property High Court. The Supreme Court made a decision to take the appeal petitioned by the generic companies and rendered the judgment to dismiss the appeal from the decision of Intellectual Property High Court. Thereby, Chugai's victory in the lawsuit seeking injunction of the generic products has become final. Chugai is now seeking recovery of damages caused by the infringement of Patent against 3 generic companies in a lawsuit at Tokyo District Court. Meanwhile, the lawsuit above is expected to be negligible on the business performance of Chugai.

Similar Private Companies By Industry

Company Name Region
ABsize Inc. Asia
AccuRna, Inc. Asia
ACE Japan, L.L.C. Asia
AETAS Pharma Co.,Ltd. Asia
AIP Corporation Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Takata Seiyaku Co., Ltd., please visit www.takata-seiyaku.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.